Management of Advanced Small Bowel Cancer
- 113 Downloads
Small bower cancer is a rare disease, despite its incidence is increasing in the last decade. Both benign and malignant tumors can arise from the small intestine. The main histological cancer types are adenocarcinomas, neuroendocrine tumors, sarcomas, gastrointestinal stromal tumors (GISTs), and lymphomas. Due to the rarity of these malignances, all the currently available data are based on small studies or retrospective series, although recent breakthroughs are redirecting our approach to these patients. Immunotherapy for small bowel adenocarcinomas, several multikinase inhibitors in resistant GIST patients, as well as everolimus and 177Lu-DOTATATE in neuroendocrine tumors are only few of the novel therapeutic options that have changed, or may change in the future, the therapeutic landscape of these rare cancers. Larger and more powerful studies on the molecular profile of these tumors may lead to a better design of clinical trials, which eventually would provide our patients with more efficacious treatments to improve both overall survival and quality of life.
KeywordsSmall bowel cancer Adenocarcinoma GIST Neuroendocrine
AP and FB drafted the manuscript. H-JL supervised the manuscript. All authors directly provided their contribution, read, and approved the final manuscript.
This manuscript was partly supported in part by the National Cancer Institute (grant number P30CA014089), the Gloria Borges WunderGlo Foundation-The Wunder Project, the Dhont Family Foundation, the San Pedro Peninsula Cancer Guild, the Daniel Butler Research Fund, and the Call to Cure Research Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
Compliance with Ethical Standards
Conflict of Interest
Alberto Puccini declares that he has no conflict of interest.
Francesca Battaglin declares that she has no conflict of interest.
Heinz-Josef Lenz has received clinical trial financial support from Merck Serono and Roche and honoraria for advisory board membership and lectures from Bayer, Boehringer Ingelheim, Genentech, Merck Serono, and Roche.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Ethics Approval and Consent to Participate
Consent for Publication
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.https://seer.cancer.gov/statfacts/html/smint.html. SCSFSICNCI.
- 4.Severson RK, Schenk M, Gurney JG, et al. Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults. Cancer Epidemiol Biomark Prev. 1996;5:81–4.Google Scholar
- 23.National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon Cancer. Version 3.2018. Avalable at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Last Accessed 01 Sept 2018.
- 24.• Locher C, Batumona B, Afchain P, et al. Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2018;50:15–9 Updated clinical guidelines for the management of small bowel adenocarcinoma.PubMedGoogle Scholar
- 33.Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol). 2007;19:143–9.Google Scholar
- 46.McWilliams RR, Foster NR, Mahoney MR, et al. North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 2017;123:3494–501.PubMedPubMedCentralGoogle Scholar
- 47.Zaanan A, Gauthier M, Malka D, Locher C, Gornet JM, Thirot-Bidault A, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer. 2011;117:1422–8.PubMedGoogle Scholar
- 52.Falcone R, Roberto M, Filetti M, Anselmi E, Marchetti P. Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: case report and literature review. Medicine (Baltimore). 2018;97:e9672.Google Scholar
- 58.Rovers KP, de Bree E, Yonemura Y, de Hingh IH. Treatment of peritoneal metastases from small bowel adenocarcinoma. Int J Hyperth. 2017;33:571–8.Google Scholar
- 60.Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(suppl LBA3503). https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503.
- 68.Lenke LG, Engsberg JR, Ross SA, Reitenbach A, Blanke K, Bridwell KH. Prospective dynamic functional evaluation of gait and spinal balance following spinal fusion in adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2001;26:E330–7.Google Scholar
- 74.Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.PubMedGoogle Scholar
- 85.Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.PubMedGoogle Scholar
- 87.Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–12.PubMedGoogle Scholar